News Enhertu extends survival in advanced gastric cancer Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.
News Takeda scores with polycythemia vera drug in phase 3 trial A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.
News Owkin launches ATLANTIS patient data mining project Owkin has partnered 20 healthcare institutions on a patient data mining project, ATLANTIS, across oncology, immunology/inflammation, and neurology.
News Regeneron tries again with lymphoma bispecific in US Regeneron has refiled its CD20xCD3 bispecific odronextamab for lymphoma with the FDA, which was rejected last year, but is seeking a narrower label.
News Can Keytruda finally break into early head and neck cancer? The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.
News Perlmutter's Eikon raises $351m in major financing round Eikon has added to its already copious cash reserves with a $351m round for its expanding pipeline of cancer therapies.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
